The effects of the competitive N methyl-o-aspartate (NMD A) receptor antagonist 0-(E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid (o-CPP-ene; SDZ EAA 494) upon ischemic brain damage have been examined in anesthetized cats. Focal cerebral ischemia was produced by permanent occlusion of the middle cerebral artery (MCA) and the animals were killed 6 h later. The amount of early ischemic brain dam age was assessed in coronal sections at 16 predetermined stereotaxic planes. Pretreatment with o-CPP-ene (15 mg/ kg i. v. followed by continuous infusion at 0.17 mg/kg/min
Excessive activation of glutamate receptors ap pears to be a crucial factor in the sequence of cel lular events leading to irreversible ischemic damage to neurons (Meldrum, 1985; Rothman and Olney, 1986) . There is now considerable evidence that treatment with glutamate receptor antagonists, par ticularly antagonists of the N-methyl-D-aspartate (NMDA) receptor subtype, can reduce ischemic until death), 15 min prior to MCA o cclusion, significantly reduced the volume of ischemic brain damage (from 20.6 ± 9.9% of the cerebral hemisphere in vehicle-treated cats to 7.2 ± 4.4% in drug-treated cats; p < 0.01). The com petitive NMDA receptor antagonist o-CPP-ene is as ef fective as noncompetitive NMDA antagonists in reducing the amount of ischemic brain damage in this model of focal cerebral ischemia in a gyrencephalic species. Key Words: Cerebral ischemia-Cerebrovascular disease Glutamate-N-Methyl-o-aspartate antagonists brain damage in animal models of focal cerebral ischemia (Germano et aI., 1987; Gotti et aI., 1988; Ozyurt et aI., 1988; Park et aI., 1988a,b; Steinberg et aI., 1988) .
There are a number of distinct sites within the NMDA receptor-ion channel complex at which drugs may act to attenuate the effect of glutamate (Foster and Fagg, 1987) . Agents such as MK-801, TCP, and PCP appear to interact with a site within the ion channel of the NMDA receptor to produce noncompetitive blockade of the action of glutamate (Kemp et aI., 1987) . Agents such as 7-chloro kynurenic acid appear to attenuate the effects of NMDA receptor agonists by acting at a site through which glycine allosterically enhances receptor func tion (Kemp et aI., 1988) . Other allosteric sites (the "polyamine site") may be involved in the actions of ifenprodil and related compounds on the NMDA receptor complex (Carter et aI., 1989) . However, conceptually, the most simple site at which NMDA antagonists can exert their action is the neurotrans mitter site at which agonists such as NMDA and glutamate act (Foster and Fagg, 1987) . Although an tagonists that act competitively at the glutamate recognition site [e.g., AP5, AP7, 4-(3-phosphono propyl)piperazine-2-carboxylic acid (CPP)] have been known for a number of years, these agents are of minimal therapeutic interest because of their poor penetration through the blood-brain barrier or relatively low potency (Meldrum, 1985; Watkins and Olverman, 1987) . Recently, potent brain penetrating competitive NMDA antagonists (CGS 19755, SDZ EAA 494) have been developed (Leh mann et aI., 1988; Aebischer et aI., 1989) . SDZ EAA 494 is the o-enantiomer 0-(E)-4-(3-phos phonoprop-2-enyl)piperazine-2-carboxylic acid (0-CPP-ene), an unsaturated analogue of CPP. Ligand binding studies and in vitro electrophysiological in vestigations on rat cerebral cortex demonstrate that o-CPP-ene has a selective and competitive action at NMDA receptors that is approximately 10 times more potent than CPP itself, with an affinity for the NMDA recognition site among the highest yet de scribed (Aebischer et aI., 1989; Lowe et aI., 1990) . In this report we have sought to establish whether a competitive NMDA antagonist, o-CPP-ene, is ef fective in reducing histologically defined ischemic brain damage in a model of focal cerebral ischemia in the cat, a model in which noncompetitive antag onists display potent antiischemic effects (Gotti et aI., 1988; Ozyurt et aI., 1988; Park et aI., 1988a,b) .
MATERIALS AND METHODS
The investigations were carried out in 12 cats weighing between 2.4 and 3.5 kg. Each cat was anesthetized (Saf fan, 9 mglkg i.v. total steroids), intubated, and connected to a positive pressure ventilator delivering nitrous oxide and oxygen in an open circuit. Polyethylene catheters were inserted into two femoral veins and an artery for the administration of drugs and the continuous monitoring of arterial blood pressure, respectively. Anesthesia was maintained throughout the course of the investigation with chloralose (60 mglkg i.v. supplemented as necessary to prevent the return of the corneal reflex). The cat's head was placed in a stereotaxic frame. Throughout the exper imental period, the animals were maintained normoten sive (MABP of >75 mm Hg) by tilting the operating table to increase the inclination of the cat's trunk and hind limbs. Normocapnia (Pac02 close to 32 mm Hg) was maintained by adjusting the stroke volume of the respira tor. Metabolic acidosis was corrected by administration of sodium bicarbonate (8.4%). Core temperature was maintained constant by a rectal thermistor probe and con trol heating pad (Table 1) . Regular samples of arterial blood were taken for the determination of respiratory sta tus (using a direct reading electrode system) and plasma glucose (automated assay based on the glucose oxidase reaction).
The left middle cerebral artery (MCA) was occluded via a transorbital approach. With microsurgical tech niques, the left orbit was exenterated and the orbital roof and optic foramen were removed with a dental drill to expose the dura mater overlying the MCA from its origin. Under the operating microscope the dura was incised and the MCA exposed. The trunk of the MCA and all its collateral branches, including the origin of the lenticulo striate arteries, were coagulated with bipolar diathermy, and the main trunk was divided with microscissors. D-CPP-ene (15 mglkg) dissolved in saline was adminis tered as a slow (5 min) intravenous injection, 15 min be fore the occlusion of the MCA. Upon completion of the bolus injection of D-CPP-ene, a constant intravenous in fusion of the agent (0.17 mglkglmin) was begun and main tained until death of the animal. Control animals received a bolus injection of saline of similar volume to the drug (10 ml) and an intravenous infusion of saline (0.15 mll min). Control animals were treated contemporaneously and randomized with the drug-treated animals. In drug treated animals, samples of arterial blood were with drawn at hourly intervals, centrifuged, and plasma levels of drug determined by HPLC.
Six hours after occlusion of the MCA, the cat was kill ed by transcardiac perfusion-fixation with 40% formalde hyde, glacial acetic acid, and methanol (1: 1 :8) as de scribed previously (Brown and Brierley, 1968) . Briefly, the cat was placed in a supine position and heparinized. A thoracotomy was performed, a cannula introduced into the ascending aorta via the left ventricle, and the right atrium was incised. Physiological saline was infused, at a pressure equivalent to MABP, until the atrial effusate was clear (-500 mI). This was followed immediately by 1.5 L of the above-described fixative at the same pressure. Af ter perfusion, the cat was decapitated and the head was stored in the same fixative at 4°C for at least 12 h. The brain was then removed. After the left side of the fore brain was marked with Indian ink, the hindbrain was de tached by a cut through the midbrain and the cerebral hemispheres were cut into four equally spaced coronal slices. These blocks were embedded in paraffi n wax and sections 7-8 f.Lm thick were cut at 200-f.Lm intervals throughout the blocks (�150-200 sections from each fore brain). The sections were stained by hematoxylin and eosin and by a method combining cresyl violet and Luxol fast blue. Those sections that corresponded most closely to 16 stereotaxically predetermined coronal planes of cat brain from the atlas of Reinoso-Suarez (1961) were exam ined by conventional light microscopy by one of us with out prior knowledge of the animal's history. Any abnor malities were charted on anatomical diagrams. The exist ence of ischemic neuronal damage in the cerebral hemisphere, cerebral cortex, and caudate nucleus was determined from the diagrams, at each of the 16 coronal planes, using a computer-based image analysis system. The volumes of ischemic damage were calculated from the areas of damage at the different coronal planes and their anteroposterior coordinates.
In the tables and in the text, data are presented as means ± SD. In the figure, the mean ± SEM values are presented. For cardiovascular, respiratory, and other systemic variables, statistical comparison between the two experimental groups was performed using the two tailed Student's t test without Bonferroni correction. The volume of ischemic damage in the two experimental groups was compared with a one-tailed Student's t test because of the a priori decision to examine only the abil ity of the drug to reduce the volume of ischemic damage. The area of ischemic damage at each coronal plane was compared between the two groups by a two-tailed Stu dent's t test because of the possibility of bidirectional changes even when the volume is reduced.
RESULTS
The administration of D-CPP-ene elicited a small consistent decrease in MABP from 112 ± 9 mm Hg prior to drug administration to 91 ± 20 mm Hg im mediately after administration of the loading bolus of D-CPP-ene (15 mg/kg; p < 0.02, Student's paired t test). Although there was a significant difference between control animals and animals receiving the drug at only one time point (4 h after initial drug treatment), this is a reflection of more aggressive measures to maintain normotension in drug-related animals. The administration of the vehicle (saline) did not alter MABP. There were no significant dif ferences between the two groups with respect to respiratory blood gas status or rectal temperature, although there was a tendency for animals treated with D-CPP-ene to be less hyperglycemic in the later stages of the experiment (Table 1) .
The plasma level of D-CPP-ene remained con stant throughout the postocclusion period (54 ± 11 I-Lg/ml at 1 h after MCA occlusion; 57 ± 21 I-Lg/ml immediately prior to death, 6 h after MCA occlu sion).
Neuropathological examination
All brains were judged to be well perfusion-fixed as evidenced by good neuronal morphology, the ab sence of intravascular blood, and the lack of cyto-logical artifacts such as "dark cells" or "hydropic cells" (Cammermeyer, 1961; Brown and Brierley, 1968) . Coronal sectioning of the brains revealed the interior of the brains to be well fixed, other than in the deeper portions of the left hemisphere in certain animals where small zones of pink discoloration could be seen. Ischemic damage was observed only within the territory of the occluded MCA, i.e., in the dorsolateral cortex and in the neostriatum. Within these areas, almost every neuron showed the morphological characteristics of early infarc tion: microvacuolation, shrinkage and triangulation of nucleus and cytoplasm, increased basophilia of cytoplasm, and perineuronal swollen astrocytes (Brierley and Graham, 1987) . The histopathologic appearance of the ischemic tissue was similar in vehicle-treated and D-CPP-ene-treated animals.
Volumetric assessment of ischemic damage
The administration of D-CPP-ene initiated 15 min before MCA occlusion reduced the volume of isch emic damage due to occlusion of the MCA in the cerebral hemisphere (reduced by 65% from vehicle treated controls) and cerebral cortex (reduced by 76%) ( Table 2 ). The volume of ischemic damage in the caudate nucleus was altered only minimally by pretreatment with D-CPP-ene (Table 2 ). The areas of ischemic damage in the cerebral cortex and hemi sphere were reduced by D-CPP-ene to a similar de gree at each coronal plane examined, with the sta tistically significant reductions being noted between planes anterior 18 and 4 mm (Fig. 1) . The areas of ischemic damage in the caudate nucleus were not significantly modified by the drug in any plane stud ied.
DISCUSSION
The existence of multiple pharmacologically ac tive sites within the NMDA receptor-ion channel complex is not merely of esoteric neuropharmaco logical interest. The different sites within the com- plex at which noncompetitive antagonists (such as MK-80l) and competitive antagonists (such as D CPP-ene) act and the influence of glutamate upon their interactions with their specific binding sites may have a crucial bearing on the efficacy of these two types of NMDA antagonists in cerebral isch emia and upon their potential for psychoactive ef fects. Noncompetitive antagonists such as MK-801 pro duce a use-dependent blockade, whereby the bind ing of the drug to its recognition site in the ion chan nel and the resulting NMDA blockade are markedly enhanced by high concentrations of glutamate (Wong et al., 1986; Kemp et aI., 1987) . In contrast, the NMDA receptor blockade produced by compet itive antagonists such as D-CPP-ene can be over come and reduced by increasing concentrations of glutamate (Kemp et aI., 1987) . In cerebral ischemia, there is a 10-to 30-fold increase in extracellular concentrations of glutamate (Benveniste et aI., 1984) . Consequently, in cerebral ischemia, the pres ence of high extracellular glutamate levels should intensify the blockade produced by noncompetitive NMDA antagonists such as MK-801, but counteract the blockade produced by competitive antagonists such as D-CPP-ene. However, in the cat model of focal cerebral ischemia, there appears to be little difference in efficacy between MK-801 and D CPP-ene in reducing ischemic brain damage at the doses examined (Ozyurt et aI., 1988; Park et aI., 1988a; present study) .
The different sites within the NMDA receptor complex at which competitive and noncompetitive antagonists act may have an impact on their poten tial for inducing psychotic activity in addition to their effects on neuronal ischemic damage. Phen cyclidine and ketamine are known to produce non competitive blockade of the NMDA receptor, and both interact with the same binding site at which MK-801 acts, within the NMDA receptor-ion chan nel (Foster and Fagg, 1987; Sircar et aI., 1987) . The behavioral effects of noncompetitive NMDA antag onists are more marked in experimental animals than those of competitive antagonists (Koek et aI., 1988; France et aI., 1989) . Similarly the effects of noncompetitive NMDA antagonists on function related glucose use in the rat CNS are more marked and anatomically more widespread than those elic ited by competitive antagonists (Weissman et aI., 1987; Nehls et aI., 1988; Kurumaji et aI., 1989) . It remains to be established whether the CNS effects of noncompetitive and competitive NMDA antago nists in humans are qualitatively or quantitatively different at therapeutic concentrations.
In the absence of systemic dose-response curves for competitive and noncompetitive NMDA antag onists in a reliable model of cerebral ischemia, the relative efficacy of these different classes of NMDA antagonists cannot yet be addressed. Although po tency orders for NMDA receptor antagonists in re ducing neuronal damage after exposure to toxic lev els of glutamate, hypoxia, and hypoglycemia are being established in cell cultures Goldberg et al., 1988) , comparisons in vivo will be complicated by pharmacokinetics, brain penetra tion, interactions with anesthetics, and cardiovas cular side-effects. In the present experiments, steady-state plasma levels of o-CPP-ene were main tained by constant systemic infusion following a loading bolus. This regimen was adopted to over come elimination of the drug from plasma observed in pilot experiments, so that pharmacokinetic com plications were removed as far as possible from the question posed, namely, whether pretreatment with a competitive NMDA antagonist can produce neu roprotection in focal ischemia. Further work is re quired to determine whether constant plasma levels are a requirement for the demonstrated neuropro tective efficacy of o-CPP-ene in vivo. It remains to be established whether treatment with o-CPP-ene initiated after the induction of the ischemic episode is similarly effective in reducing neuronal damage.
The outcome of such a study will be critically de pendent upon adequate delivery of o-CPP-ene within the therapeutic time window to brain regions with very low blood flow [see the delay in uptake of the lipophilic eH]MK-801 into ischemic areas in the rat (Wallace et al., 1989) ]. The answer to such ques tions will have importance for a possible clinical use of competitive NMDA receptor antagonists.
Competitive and noncompetitive NMDA recep tor antagonists have marked effects on oxidative metabolism and cerebral blood flow (Nehls et al., 1988 (Nehls et al., , 1990 Park et al., 1989) . The prevailing view is that the neuroprotective properties of NMDA antagonists are not directly linked to improvements in cerebral tissue perfusion (Sauer et al., 1988; Park et al., 1989) , although this view has not gone unchallenged (Buchan et al., 1989) . However, the cerebral circulatory and met abolic effects of NMDA antagonists in anesthetized animals appear to differ from those in conscious animals Nehls et al., 1990) , and the anesthetic de pendence of these responses will complicate the elucidation of their contribution, if any, to im proved outcome after cerebral ischemia. Further more, in the present study in which the cat was anesthetized with chloralose throughout, coopera tive interaction between the anesthetic and 0-CPP-ene cannot be discounted.
The first demonstrations that the consequences of cerebral ischemia or severe hypoglycemia could be ameliorated by blockade of NMDA receptors employed intracerebral administration of competi tive antagonists (Simon et al., 1984; Wieloch, 1985) . Subsequent investigations on the role of the NMDA J Cereb Blood Flow Metab, Vol. 10, No.5, 1990 receptor in the genesis of neuronal damage have been dominated by studies with brain-penetrating noncompetitive NMDA blockers, either highly po tent and selective antagonists such as MK-801 or less potent and selective agents such as phencycli dine, TCP, and dextrophan (Gotti et al., 1988; Ozyurt et al., 1988; Park et al., 1988a,b; Sauer et al., 1988; Steinberg et al., 1988) . Investigations of the antiischemic effects of systemic administration of selective, competitive NMDA antagonists in re liable animal models are more limited. Systemic ad ministration of 2-amino-7-phosphonoheptanoate, at massive doses (three times 675 mg/kg), necessitated by its limited blood-brain barrier penetration, pro tects hippocampal neurons in a rat model of global ischemia (Swan et al., 1988) . Kynurenic acid at sim ilarly massive concentrations reduces ischemic damage in the rat cortex after MCA occlusion (Ger mano et al., 1987) . Kynurenic acid is a competitive NMDA antagonist but, in addition, blocks the gly cine site in the NMDA receptor complex as well as non-NMDA receptors (quisqualate and kainate) (Perkins and Stone, 1982; Birch et al., 1988) , which may be involved in excitotoxic damage to neurons (Frandsen et al., 1989) . CPP and CGS 19755 reduce ischemic damage in a gerbil model (Boast et al., 1988) , but the susceptibility of this model to post ischemic seizures and the potency of NMDA antag onists as anticonvulsants (Meldrum, 1985; Leh mann et al., 1988) compromise these data. The present report provides evidence that a competitive NMDA antagonist, with therapeutic potential, is ca pable of markedly reducing cortical damage in a gyrencephalic model of focal cerebral ischemia. The demonstration that pretreatment with compet itive NMDA antagonists can ameliorate the conse quences of focal cerebral ischemia as effectively as noncompetitive NMDA antagonists may have an impact on the selection of such agents for clinical evaluation in humans, where a balance between ef ficacy and safety must be achieved.
